Earnings call transcripts

Management framed Q4 as an inflection point, with stronger customer forecasts supporting accelerated 2026 growth and heavier investment.

Management framed 2025 as disciplined, product-led growth, emphasizing supply-chain leverage, diversified channels and technology alongside sustained profitability.

Management framed 2025 as an inflection point, pairing renewed growth with a lower cost base and Vision 2028 expansion priorities.

Management framed 2026 as an investment-heavy transition, with data-center demand accelerating before legacy markets recover later in the year.

Management framed 2026 as a transition year: newly won business and diversification should offset Rhythm-related attrition while EBITDA remains near flat.

Management framed 2026 around scalable core-market execution, Chicago expansion, selective acquisitions, and disciplined capital allocation despite several timing uncertainties.

Management framed 2026 as a deliberate Proteus transition year, accepting weaker near-term sales to prepare the market and prioritize development ahead of launch.

Management framed fiscal 2027 as a navigation year balancing memory constraints and promotional pressure against replacement cycles, innovation, and emerging categories.

Management framed 2025 as a commercial and financial transformation, with 2026 growth depending on direct selling, patient renewals, pump integration, and Europe.

Management framed 2026 around completing wildfire settlement approvals, reshaping PBR economics, and funding a sharply elevated utility investment cycle.

Management framed 2025 as proof of disciplined execution, with contracting and staged growth projects extending visibility while major decisions remain targeted for 2026.

Management framed 2025 as resilient despite weak Alberta pricing, while pivoting toward contracted data-center demand and preserving options for future gas generation.